Moderna (MRNA) News Today

Moderna, Inc. (NASDAQ: MRNA) shares are trading higher as investors focus on the potential of its personalized cancer vaccine platform, despite valuation concerns and recent analyst downgrades. The stock has pulled back from its post-August surge, but remains supported by optimism surrounding melanoma data and upcoming third-quarter results expected on November 6.

• Positive Sentiment: Moderna’s personalized cancer vaccine, developed with Merck, reduced melanoma recurrence risk by 42% in a Phase 3 trial. Investors remain encouraged by the clinical proof-of-concept and the possibility that the platform could be expanded to other cancers. Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
• Positive Sentiment: CEO Stéphane Bancel defended the cancer-vaccine results and said the data should improve with longer follow-up. He also argued that Moderna’s mRNA technology and manufacturing capabilities create a competitive advantage that rivals cannot easily replicate. Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time
• Positive Sentiment: Investors are watching the November 6 earnings report for evidence that Moderna’s commercial business and cash position can support continued investment in its oncology pipeline. Will Moderna Soar on Nov. 6?
• Neutral Sentiment: Presentations at the 2026 ESMO Congress reinforced the scientific interest in Moderna’s oncology program, though investors still need clearer evidence of commercial timing and revenue potential. Moderna Presents at 2026 ESMO Annual Congress
• Negative Sentiment: William Blair downgraded Moderna to Market Perform from Outperform, citing valuation after the stock’s major rally. Another analyst also lowered the FY2028 EPS estimate, highlighting concerns that expectations may have advanced faster than near-term earnings. Moderna Rating Lowered to Market Perform at William Blair